Skip to main content

Development of a systems biomedicine approach for risk identification, prevention and treatment of type 2 diabetes

Objective

Type 2 diabetes (T2D) is a major public health problem, affecting 55 million European citizens. T2D ensues in individuals who develop a progressive pancreatic beta cell failure. T2D probably comprises a heterogeneous group of diseases. A new molecular taxonomy of T2D is essential for the development of medical care that is predictive, preventive and personalized. Currently available T2D therapies are not disease modifying: they treat hyperglycaemia without addressing its underlying cause, i.e. beta cell failure. In this proposal we seek to identify pathogenic molecular events that operate in the diseased tissue, i.e. the failing human beta cell, at their true level of complexity. T2DSystems will accomplish this ambitious goal by integrating human islet genetic and epigenetic data with disease-relevant environmental perturbations, metabolomics and functional studies, and use this knowledge to identify distinct human islet phenotypes in subgroups of patients. In closely interacting work packages, we will achieve the following goals:
• Compile and expand existing European bio-banks and datasets to create the Translational human pancreatic Islet Genotype tissue-Expression Resource (TIGER), a T2D systems biomedicine resource of unprecedented scale;
• Develop large-scale data analysis tools and both data driven and mechanistic probabilistic modelling frameworks to exploit TIGER towards system level biological insight;
• Translate these findings to identify stratified beta cell phenotypes in human cohorts. This will provide understanding of beta cell pathophysiology in vivo and enable stratified prevention and therapeutics.
T2DSystems will enable the development of personalized diagnostic tests, taking into account individual environmental and genetic risk factors. The newly identified molecular disease mechanisms will provide the basis for development of novel therapies and for patient stratification to test individualized therapies.

Field of science

  • /medical and health sciences/health sciences/public and environmental health
  • /medical and health sciences/basic medicine/physiology/pathophysiology
  • /medical and health sciences/clinical medicine/endocrinology/diabetes
  • /natural sciences/computer and information sciences/data science/data analysis

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

UNIVERSITE LIBRE DE BRUXELLES
Address
Avenue Franklin Roosevelt 50
1050 Bruxelles
Belgium
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 504 957,77

Participants (11)

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 633 418,75
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Participation ended

Spain
EU contribution
€ 402 829,98
Address
Calle Rossello 149 Puerta Bjs
08036 Barcelona
Activity type
Other
UNIVERSITA DI PISA
Italy
EU contribution
€ 517 722,50
Address
Lungarno Pacinotti 43/44
56126 Pisa
Activity type
Higher or Secondary Education Establishments
LUNDS UNIVERSITET
Sweden
EU contribution
€ 589 667,50
Address
Paradisgatan 5C
22100 Lund
Activity type
Higher or Secondary Education Establishments
KOBENHAVNS UNIVERSITET
Denmark
EU contribution
€ 488 492,50
Address
Norregade 10
1165 Kobenhavn
Activity type
Higher or Secondary Education Establishments
BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION
Spain
EU contribution
€ 451 961,25
Address
Calle Jordi Girona 31
08034 Barcelona
Activity type
Research Organisations
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Participation ended

United Kingdom
EU contribution
€ 118 179
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
INTOMICS AS
Denmark
EU contribution
€ 471 486,25
Address
Lottenborgvej 26
2800 Kgs Lyngby
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SIRION BIOTECH GMBH
Germany
EU contribution
€ 454 500
Address
Am Klopferspitz 19
82152 Planegg Martinsried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
A2F ASSOCIATES LIMITED
United Kingdom
EU contribution
€ 186 150
Address
7 Laureate Paddocks
CB8 0AP Newmarket
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACIO CENTRE DE REGULACIO GENOMICA
Spain
EU contribution
€ 179 237
Address
Carrer Doctor Aiguader 88
08003 Barcelona
Activity type
Research Organisations